Is There Clinical Value to Prognostic Signatures in Early-Stage NSCLC?

被引：4

作者：

Bunn, Paul A., Jr. ^{[1
]}

Hirsch, Fred R. ^{[1
,2
]}

Aisner, Dara L. ^{[2
]}

机构：

[1] Univ Colorado Denver, Univ Colorado Canc Ctr, Dept Med, Div Med Oncol, Aurora, CO 80045 USA

[2] Univ Colorado Denver, Univ Colorado Canc Ctr, Dept Pathol, Aurora, CO 80045 USA

来源：

CLINICAL CANCER RESEARCH | 2014年 / 20卷 / 07期

关键词：

CELL LUNG-CANCER; ADJUVANT CHEMOTHERAPY; PREDICT SURVIVAL; VALIDATION; ASSAY; RISK;

D O I：

10.1158/1078-0432.CCR-13-3387

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

pAMPK and pmTOR favorably predicted outcome in early non-small cell lung cancer (NSCLC). The differences were small. Phosphoprotein lability makes routine clinical use and validation difficult. Protein immunohistochemistry is unlikely to be clinically useful, and numerous efforts to create predictive models to select resected patients for therapy have been unsuccessful. (C) 2014 AACR.

引用

页码：1727 / 1729

页数：3

共 50 条

[41] Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC [J].

Brooks, Eric D. ;

Verma, Vivek ;

Senan, Suresh ;

De Baere, Thierry ;

Lu, Shun ;

Brunelli, Alessandro ;

Chang, Joe Y. .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) :176-189

[42] Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC [J].

Frampton, James E. .

TARGETED ONCOLOGY, 2022, 17 (03) :369-376

[43] Neoadjuvant immunotherapy in early-stage NSCLC: navigating biomarker dilemmas and special population challenges [J].

Chen, Tong ;

Liu, Fang .

LUNG CANCER, 2025, 204

[44] Combination of ctDNA and PET identify patients at risk for relapse with irradiated early-stage NSCLC [J].

Nakamura, Masaki ;

Kageyama, Shun-ichiro ;

Hirata, Hidenari ;

Tochinai, Taku ;

Hojo, Hidehiro ;

Motegi, Atsushi ;

Kanai, Akinori ;

Suzuki, Yutaka ;

Tsuchihara, Katsuya ;

Akimoto, Tetsuo .

RADIOTHERAPY AND ONCOLOGY, 2024, 197 :S48-S49

[45] Waiting times in early-stage non-small cell lung cancer (NSCLC) [J].

Saint-Jacques, Nathalie ;

Rayson, Daniel ;

Al-Fayea, Turki ;

Virik, Kiran ;

Morzycki, Wojciech ;

Younis, Tallal .

JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (08) :865-870

[46] Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC [J].

Moreno, Amy C. ;

Fellman, Bryan ;

Hobbs, Brian P. ;

Liao, Zhongxing ;

Gomez, Daniel R. ;

Chen, Aileen ;

Hahn, Stephen M. ;

Chang, Joe Y. ;

Lin, Steven H. .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (01) :101-109

[47] SEOM clinical guidelines in early-stage breast cancer 2015 [J].

Garcia-Saenz, J. A. ;

Bermejo, B. ;

Estevez, L. G. ;

Palomo, A. G. ;

Gonzalez-Farre, X. ;

Margeli, M. ;

Pernas, S. ;

Servitja, S. ;

Rodriguez, C. A. ;

Ciruelos, E. .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (12) :939-945

[48] Prognostic Value of Serum Tumor Markers in Patients With Stage III NSCLC Treated With Chemoradiotherapy [J].

Tokito, Takaaki ;

Azuma, Koichi ;

Yamada, Kazuhiko ;

Naito, Yoshiko ;

Matsuo, Norikazu ;

Ishii, Hidenobu ;

Natori, Hiroki ;

Kinoshita, Takashi ;

Hoshino, Tomoaki .

IN VIVO, 2019, 33 (03) :889-895

[49] Clinical Utility of Genomic Assay in Node-Positive Early-Stage Breast Cancer [J].

Pauls, Mehrnoosh ;

Chia, Stephen .

CURRENT ONCOLOGY, 2022, 29 (07) :5139-5149

[50] Drugs in preclinical and early-stage clinical development for pancreatic cancer [J].

Asuthkar, Swapna ;

Rao, Jasti S. ;

Gondi, Christopher S. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (02) :143-152

← 1 2 3 4 5 →